P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

A 14-protein blood test can identify people at high risk of lung cancer more than 5 years before a tumor becomes detectable on imaging, including never-smokers who fall outside current screening criteria. In a retrospective analysis, the test also identified individuals most likely to benefit from the anti-IL-1β drug canakinumab, which roughly halved lung cancer incidence in the high-risk group but not in low-risk participants.

Pretreatment CD4+ T-cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T-cell composition.

P=N/A, N=160, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2027 --> Dec 2026 | Trial primary completion date: Mar 2027 --> Dec 2026

P1, N=12, Recruiting, University of Michigan Rogel Cancer Center | Not yet recruiting --> Recruiting

When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.

P3, N=52, Not yet recruiting, R-Pharm International, LLC

Although the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial demonstrated reduced lung cancer incidence with interleukin (IL)-1β inhibition, the high number needed to treat (NNT) to prevent lung cancer limits its use in unselected populations...Components of the signature were induced by PM, oncogenic EGFR, or IL-1β, whereas IL-1β inhibition restrained PM-driven KAC expansion and early tumorigenesis. In CANTOS, the signature identified individuals who seemed to benefit more from anti-IL-1β therapy, lowering the NNT threshold and nominating circulating signals of tumor promotion for prevention.

P3, N=1400, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting

P=N/A, N=30, Not yet recruiting, The First Affiliated Hospital of Soochow University

CRBN-targeting immunomodulatory drugs (IMiDs), including lenalidomide and pomalidomide, are widely used in hematologic malignancies but are associated with an elevated risk of venous thromboembolism (VTE). Early-onset PE risk is mechanistically linked to vascular endothelial injury and inflammatory signaling, supporting the use of dynamic risk stratification tools (e.g., IMPEDE-VTE score) and early DOAC intervention. Public health policy should integrate molecular insights with real-world surveillance to optimize clinical safety frameworks for oncology patients.

P=N/A, N=160, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Sep 2026 --> Mar 2027 | Trial primary completion date: Sep 2026 --> Mar 2027